More Than 200 Abstracts Evaluating Celgene Products across a Range of Indications to Be Presented at the 51st American Society of Hematology Meeting
SUMMIT, N.J.--(BUSINESS WIRE)--Nov 11, 2009 - Celgene Corporation (NASDAQ: CELG) today announced that clinical investigators from leading hematology research centers around the world will present data from more than 200 recent and on-going clinical trials of Celgene products including REVLIMID®, VIDAZA®, THALOMID®, pomalidomide, ACE-011 and Amrubicin at the 51st Annual American Society of Hematology Meeting and Exposition from December 5-8, 2009 in New Orleans, Louisiana.
Clinical and scientific abstracts will be presented in oral and poster sessions as an exchange of recent and updated scientific and clinical data and will report important new results in indications such as multiple myeloma, non-Hodgkin's lymphoma, chronic lymphocytic leukemia, acute myeloid leukemia and myelodysplastic syndromes.
For more information and for complete abstracts, please visit http://ash.confex.com/ash/2009/webprogram/start.html
Celgene Corporation, based in Summit, New Jersey, is an integrated global biopharmaceutical company engaged primarily in the discovery, development and commercialization of novel therapies for the treatment of cancer and inflammatory diseases through gene and protein regulation. For more information, please visit the Company's website at www.celgene.com.
This release contains certain forward-looking statements which involve known and unknown risks, delays, uncertainties and other factors not under the Company's control. The Company's actual results, performance, or achievements could be materially different from those projected by these forward-looking statements. The factors that could cause actual results, performance, or achievements to differ from the forward-looking statements are discussed in the Company's filings with the Securities and Exchange Commission, such as the Company's Form 10-K, 10-Q and 8-K reports. Given these risks and uncertainties, you are cautioned not to place undue reliance on the forward-looking statements.
Contact: Celgene Corporation
David W. Gryska, 908-673-9059
Senior Vice President and Chief Financial Officer
Brian P. Gill, 908-673-9530
Vice President, Corporate Communications
Posted: November 2009